05 Nov Planning Around Bloating: What Akkermansia Research Shows, With Ellekay as a Label Example
Supplement Notice: These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Supplements are not a substitute for regular medical checkups or professional healthcare. Do not delay seeking medical evaluation or treatment by taking supplements. Some supplements should not be taken if you are pregnant, nursing, or may become pregnant. Supplements may interact with prescription medications and other drugs — always inform your physician or qualified healthcare provider about any and all supplements you are taking. Always consult your healthcare provider before beginning any new supplement regimen, especially if you have an existing health condition or take other medications. Prebiotic fibers such as inulin can increase gas or bloating in some people.
Editorial Notice: This article is general information and is not specific medical advice. Products and brands named or linked in this article are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Bloating is a frequent reason people start reading about gut bacteria, and Akkermansia muciniphila has become a regular name in that reading. This guide separates what the research supports from what product copy can imply, then turns it into a plan you can run yourself. It uses Ellekay, a women's wellness brand whose single product, Morning Skinny, is a digestive support capsule with Akkermansia, nine digestive enzymes and four botanical extracts, as a worked example of label reading. As of November 2026, the human evidence on this bacterium is still early.
Akkermansia muciniphila is a bacterium found in the human gut, and researchers study it as part of the wider microbiome, the community of microbes that live in the digestive tract.
Dr. Steenson[/caption]
Dr. Simon Steenson PhD
Postdoctoral Research Associate
Department of Nutritional Sciences
King’s College London
MedicalResearch.com: What is the background for this study?
Response: Chronic constipation is something that can be embarrassing, but it affects 1 in 10 people globally. It has a big impact on people’s quality of life and treating constipation has substantial costs for the healthcare system. Dried fruits are recommended for managing constipation, but there are very few studies that have actually tested whether following this advice is helpful. To fill this gap in our knowledge, we completed the largest clinical trial to date to see whether dried fruits and fruit juices could benefit constipation symptoms.
Dr. Corley[/caption]
Douglas Corley, MD, PhD
Chief Research Officer, The Permanente Medical Group
Kaiser Permanente, Northern California
MedicalResearch.com: What is the background for this study?
Response: Kaiser Permanente Northern California (KPNC) is an integrated health care system that designs and implements population-based programs that support cancer prevention and early detection. In 2006, KPNC began to implement a comprehensive colorectal cancer screening program with the goal of increasing member screening rates, preventing colorectal cancer through polyp removal, and reducing cancer mortality. The initiative identifies whether screening-eligible KPNC members are up to date with their colorectal cancer screening test by either a colonoscopy or by stool-based tests, such as a fecal immunochemical testing (FIT) kit. If they are not up to date with screening, it mails them a FIT kit for at-home testing. Members can also choose other options for colorectal cancer screening, such as a colonoscopy, through their physician.
Dr. Moyland[/caption]
Cynthia Moylan, MD
Associate Professor of Medicine,
Division of Gastroenterology
Duke University Health System
MedicalResearch.com: What is the background for this study?
Response: Metabolic dysfunction can lead to several health problems including metabolic dysfunction associated steatotic liver disease (MASLD), is driven by different factors, including: a person’s behavioral or lifestyle factors, environmental factors, and genetics. Limited research exists regarding genetic , epigenetic, or other factors that might impact development of metabolic dysfunction and MASLD. Our group has previously shown that alterations in DNA methylation (a type of epigenetic change), identifiable both in liver tissue and in blood, associate with MASLD and its progression to more severe liver disease. Whether DNA methylation that impacts imprinted gene expression also associates with metabolic dysfunction and MASLD risk remains largely unknown.
In this project, we explored imprinted genes: imprinting is a normal process that regulates genes by silencing one parental copy (either the maternal or the paternal) so that only one copy is expressed. Imprinting is an important biological process for development and has a disproportionate impact on disease - in fact, imprinted genes are hypothesized to affect 1-6% of the human genome. We sought to explore how altered DNA methylation of imprint control regions (ICRs) that help ‘control’ these imprinted genes might impact development of metabolic dysfunction in children (and hence potentially even in adults).